Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients

Fig. 3

The effectiveness of prognostic risk model. (A) The ROC of the prognostic risk model. (B) The 1-, 2-, and 3-year ROC of the prognostic risk model. (C) The ROC of the prognostic risk model. The best cut-off point was displayed. (D-E) The distribution of the survival status (D) and risk scores (E). (F) Kaplan-Meier analysis of PAAD patients in high- and low-risk groups

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us